罗氏制药83亿美元收购intermune
Swiss pharmaceutical giant Roche has said it will buy maker of lung disease therapies InterMune for $8.3bn.
瑞士医药巨头罗氏集团将要以83亿美元的价格收购肺部疾病药品生产商InterMune。
Intermune, which is based in Brisbane, California, makes a medicine for idiopathic（先天的） pulmonary fibrosis（肺纤维化）, a deadly disease which scars the lungs.
The deal is the latest in a string of mergers in the drugs sector.
It is also the largest by Roche since 2009 when it bought the remainder of Genentech for about $47bn.
Pharmaceutical mergers
Roche will pay $78 per share in InterMune, which is a premium of 38% on top of the value of the shares at the end of last week.
Recent deals in the drug sector include US drug firm AbbVie's purchase of the UK pharmaceutical company Shire for £32bn.
UK High Street chemist Alliance Boots was bought up by US pharmacy giant Walgreens in an agreement earlier this month.
In May, pharmaceutical company Pfizer dropped a bid for UK company AstraZeneca.